Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Up – Here’s What Happened

Shares of Zealand Pharma A/S (OTCMKTS:ZLDPF) gapped up prior to trading on Tuesday. The stock had previously closed at $34.5965, but opened at $36.80. Zealand Pharma A/S shares last traded at $36.75, with a volume of 600 shares.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on ZLDPF. Zacks Research cut shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Tuesday. Barclays downgraded shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 8th. Finally, Wells Fargo & Company restated an “overweight” rating on shares of Zealand Pharma A/S in a report on Thursday, August 13th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, Zealand Pharma A/S has an average rating of “Hold”.

Zealand Pharma A/S Price Performance

The company has a market cap of $2.63 billion, a P/E ratio of 6.09 and a beta of 0.99. The company has a quick ratio of 13.98, a current ratio of 13.98 and a debt-to-equity ratio of 0.02. The company has a fifty day moving average of $38.85 and a 200 day moving average of $46.81.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last posted its earnings results on Thursday, November 12th. The company reported ($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.57) by $1.45. Zealand Pharma A/S had a return on equity of 17.56% and a net margin of 58.86%. On average, research analysts anticipate that Zealand Pharma A/S will post 3.65 earnings per share for the current fiscal year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a biotechnology company headquartered in Copenhagen, Denmark. Founded in 1998, it discovers and develops peptide-based medicines, with a focus on metabolic diseases and rare conditions. The company’s portfolio has included Zegalogue (dasiglucagon), an injectable treatment approved in the United States for severe hypoglycemia in people with diabetes. Zealand also develops investigational medicines for areas such as obesity, liver disease and rare gastrointestinal disorders, and works with pharmaceutical partners to advance and commercialize selected programs.